2022-500540-38-00CompletedPhase 1
A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Dec 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- First submitted
- 23 Aug 2022
- Start date
- 27 Jun 2023
- Lead sponsor
- Novartis Pharma AG
- EU CT number
- 2022-500540-38-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 88
- 5 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cliniques Universitaires Saint-Luc | Sint-Lambrechts-Woluwe | Belgium | Completed |
| Universitaetsklinikum Essen (AoR) | Essen | Germany | Completed |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Completed |
| Institut Curie | Paris | France | Completed |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.